Oruka Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Basic Share
Oruka Therapeutics, Inc. (ORKA) reported Income (Loss) from Continuing Operations, Per Basic Share of -$1.94 per share for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2013-03-21
- Oruka Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2012-09-30 was -$0.07.
- Oruka Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2012-06-30 was -$0.09, a 400.00% decline year-over-year.
- Oruka Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2011-09-30 was -$0.17.
- Oruka Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2011-06-30 was $0.03.
- Oruka Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2012 was -$1.94.
- Oruka Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2011 was -$3.21.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$1.94 10-K · filed 2013-03-21 | |||
| 2012-09-30 | -$0.07 10-Q · filed 2012-11-13 | -$0.27 10-Q · filed 2012-11-13 | ||
| 2012-06-30 | -$0.09 10-Q · filed 2012-08-13 | -$0.21 10-Q · filed 2012-08-13 | ||
| 2011-12-31 | -$3.21 10-K · filed 2013-03-21 | |||
| 2011-09-30 | -$0.17 10-Q · filed 2012-11-13 | -$0.38 10-Q · filed 2012-11-13 | ||
| 2011-06-30 | $0.03 10-Q · filed 2012-08-13 | -$0.20 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |